Drug Profile
KRL 104
Alternative Names: KRL-104Latest Information Update: 17 May 2016
Price :
$50
*
At a glance
- Originator Krele Pharmaceuticals
- Developer Tonix Pharmaceuticals Inc
- Class Anxiolytics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Generalised anxiety disorder
Most Recent Events
- 26 Mar 2009 Clinical trials in Generalised anxiety disorder in USA (unspecified route)